Table 1

Clinicopathological features and expression of Hh pathway-related molecules in the 52 breast carcinoma specimens

Clinicopathological featuresNo. of specimensNo. of positive specimens% nuclear staining of Gli1*P
ShhPtchGli1
Age (yrs)
 <40333376.00 ± 14.530.0039
 40–704444424437.16 ± 20.82
 >70555559.20 ± 11.73
T classification
 pT13131293139.16 ± 20.82n.s.§
 pT22121212144.95 ± 20.77
Histologic type
 Intraductal carcinoma555526.60 ± 11.670.0216§
 Invasive ductal carcinoma4646444643.39 ± 21.02
 Invasive lobular carcinoma111129.00
Estrogen receptor status
 Negative1313121326.31 ± 18.010.0036§
 Positive3939383946.56 ± 19.30
Lymph node involvement
 Negative3737363739.60 ± 20.43n.s.§
 Positive1515141545.20 ± 21.64
pTNM stage
 I2323222338.52 ± 21.35n.s.
 IIA2222212240.84 ± 19.37
 IIB777752.14 ± 22.59
Total5252505240.87 ± 20.71
  • * (No. of Gli1-nuclear–staining carcinoma cells/100 carcinoma cells) × 100. The data represent mean % ± SD.

  • Kruskal-Wallis test.

  • According to the TNM classification system of International Union against Cancer.

  • § Mann-Whitney U test; n.s., not significant.

  • Abbreviation: pTNM, pathological Tumor-Node-Metastasis.